{
    "clinical_study": {
        "@rank": "164887", 
        "arm_group": {
            "arm_group_label": "Ipilimumab and GM-CSF", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both\n      ipilimumab and GM-CSF are intended to work with the body's own immune system to attack\n      melanoma cells in the body. This study will also demostrate how safe the combined drugs are\n      when used to treat patients with Stage 3 or Stage 4 melanoma (metastatic melanoma), which\n      cannot be removed by surgery."
        }, 
        "brief_title": "A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients", 
        "condition": [
            "Stage IIIC Melanoma", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients may be entered in the study only if they meet all of the following criteria.\n\n               1. Male or female patients \u226518 years of age;\n\n               2. Patients with histological confirmed melanoma (Stage IIIC or Stage IV, American\n                  Joint Commission on Cancer);\n\n               3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2;\n\n               4. Life expectancy \u22653 months;\n\n               5. At least 1 site of radiographically measurable disease by immune-related\n                  response criteria (irRC);\n\n               6. Adequate hematologic, renal, and liver function as defined by laboratory values\n                  performed within 42 days prior to initiation of dosing:\n\n                    -  Absolute neutrophil count (ANC) \u22651.0 x 109/L;\n\n                    -  Platelet count \u226550 x 109/L;\n\n                    -  Hemoglobin \u22658 g/dL;\n\n                    -  Serum creatinine \u22643 x upper limit of normal (ULN)\n\n                    -  Total serum bilirubin \u22642 x ULN;\n\n                    -  Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase\n                       (ALT/SGPT) \u22642x ULN, and \u22643 x ULN if liver metastases are present.\n\n               7. Fertile males should use an effective method of contraception during treatment\n                  and for at least 3 months after completion of treatment, as directed by their\n                  physician;\n\n               8. Pre-menopausal females and females <2 years after the onset of menopause should\n                  have a negative pregnancy test at Screening. Pre-menopausal females must agree\n                  to use an acceptable method of birth control from the time of the negative\n                  pregnancy test up to 90 days after the last dose of study drug.  Females of\n                  non-childbearing potential may be included if they are either surgically sterile\n                  or have been postmenopausal for \u22651 year;\n\n               9. Before study entry, written informed consent must be obtained from the patient\n                  prior to performing any study-related procedures.\n\n        Exclusion Criteria:\n\n          -  Patients will not be entered in the study for any of the following:\n\n               1. Treatment with Denileukin Diftitox within 42 days prior to the start of\n                  Ipilimumab;\n\n               2. Prior treatment with Ipilimumab;\n\n               3. Known hypersensitivity to Ipilimumab or any of its components\n\n               4. Received radiotherapy for non CNS disease within the 2 weeks prior to commencing\n                  study treatment or have not recovered from side effects of all radiation-related\n                  toxicities to Grade \u22641, except for alopecia;\n\n               5. Steroids within one week prior to initiation of Ipilimumab.\n\n               6. Pre-existing autoimmune colitis.\n\n               7. Patients with an allograft requiring immunosuppression;\n\n               8. Known positive human immunodeficiency virus (HIV)\n\n               9. Pregnant, breast-feeding, or refusing double barrier contraception, oral\n                  contraceptives, or avoidance of pregnancy measures;\n\n              10. Have any other uncontrolled infection or medical condition that could interfere\n                  with the conduct of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009397", 
            "org_study_id": "BCC-MEL-11-02 (Ipi2)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ipilimumab and GM-CSF", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ipilimumab and GM-CSF", 
                "intervention_name": "GM-CSF", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "contact": {
                "email": "ctobcc@louisville.edu", 
                "last_name": "Brown Cancer Center Clinical Trials Office", 
                "phone": "502-562-3429"
            }, 
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40202"
                }, 
                "name": "James Graham Brown Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients", 
        "overall_contact": {
            "email": "ctobcc@louisville.edu", 
            "last_name": "Brown Cancer Center Clinical Trials Office", 
            "phone": "502-562-3429"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Immune-related overall response rate (irORR)", 
            "safety_issue": "Yes", 
            "time_frame": "assessed at baseline and at 4 weeks (\u00b11 week) following the last administration of Ipilimumab"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "James Graham Brown Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Louisville", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "James Graham Brown Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}